Dr. Kristin Ann Meliambro, MD

Dr. Meliambro practices at Mount Sinai Doctors-Greenlawn in Greenlawn, New York.

Dr. Meliambro's NPI, 1831331263, was assigned on March 31, 2009. Dr. Meliambro graduated from Icahn School Of Medicine At Mount Sinai in 2009. Dr. Meliambro holds New York license 265391.

Dr. Meliambro's primary practice is Mount Sinai Doctors-Greenlawn, at 5 Cuba Hill Road, Greenlawn, NY 11740. The practice phone is (631) 628-5000.

Dr. Meliambro's primary practice is Mount Sinai Doctors-Greenlawn in Greenlawn, New York. Dr. Meliambro is also affiliated with The Mount Sinai Hospital. The medical group on file is Mount Sinai Doctors Long Island. Dmand AI also links Dr. Meliambro to 1 more dialysis center and 1 medical group, each named with a free account. Dr. Meliambro's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meliambro practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Meliambro's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Meliambro is licensed in New York.

CMS data shows 171 Medicare services from Dr. Meliambro across 2 procedure codes in 2024, for 69 Medicare patients. Medicare paid $18,638 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 69 Medicare patients who saw Dr. Meliambro in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 68% are also on Medicaid. Their average risk score is 9.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Meliambro's median patient age at 67, with 49% women.

In 2024, Dr. Meliambro wrote 102 Medicare Part D claims for 26 patients. 72% of them were for generic drugs. CMS names the drug for 36 of them, across 2 drugs with 11 or more claims each, at $2,158 in total drug cost. In 2023, CMS named 68 claims across 5 drugs.

Dr. Meliambro accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Coronary angioplasty and stenting: 1 to 10 procedures (CMS shows small counts as a range)

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 28 papers to Dr. Meliambro, published from 2011 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Kidney Diseases, Hippo Signaling Pathway and Intracellular Signaling Peptides and Proteins. Dr. Meliambro has published most often in Kidney Int Rep. Dr. Meliambro's most frequent co-authors are John Cijiang He, MD, Lili Chan, MD and Miriam H. Chung, MD.

CMS Open Payments shows 2 general payments to Dr. Meliambro from 2 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $120.

Dr. Meliambro graduated from Icahn School Of Medicine At Mount Sinai in 2009.